» Articles » PMID: 32297435

The EORTC QLQ-C30 Summary Score As Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry

Overview
Journal Oncologist
Specialty Oncology
Date 2020 Apr 17
PMID 32297435
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Health-related quality of life (HRQoL) has been shown to be a prognostic factor for cancer survival in randomized clinical trials and observational "real-world" cohort studies; however, it remains unclear which HRQoL domains are the best prognosticators. The primary aims of this population-based, observational study were to (a) investigate the association between the novel European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (QLQ-C30) summary score and all-cause mortality, adjusting for the more traditional sociodemographic and clinical prognostic factors; and (b) compare the prognostic value of the QLQ-C30 summary score with the global quality of life (QoL) and physical functioning scales of the QLQ-C30.

Materials And Methods: Between 2008 and 2015, patients with cancer (12 tumor types) were invited to participate in PROFILES disease-specific registry studies (response rate, 69%). In this secondary analysis of 6,895 patients, multivariate Cox proportional hazard regression models were used to investigate the association between the QLQ-C30 scores and all-cause mortality.

Results: In the overall Cox regression model including sociodemographic and clinical variables, the QLQ-C30 summary score was associated significantly with all-cause mortality (hazard ratio [HR], 0.77; 99% confidence interval [CI], 0.71-0.82). In stratified analyses, significant associations between the summary score and all-cause mortality were observed for colon, rectal, and prostate cancer, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The QLQ-C30 summary score had a stronger association with all-cause mortality than the global QoL scale (HR, 0.82; 99% CI, 0.77-0.86) or the physical functioning scale (HR, 0.81; 95% CI, 0.77-0.85).

Conclusion: In a real-world setting, the QLQ-C30 summary score has a strong prognostic value for overall survival for a number of populations of patients with cancer above and beyond that provided by clinical and sociodemographic variables. The QLQ-C30 summary score appears to have more prognostic value than the global QoL, physical functioning, or any other scale within the QLQ-C30.

Implications For Practice: The finding that health-related quality of life provides distinct prognostic information beyond known sociodemographic and clinical measures, not only around cancer diagnosis (baseline) but also at follow-up, has implications for clinical practice. Implementation of cancer survivorship monitoring systems for ongoing surveillance may improve post-treatment rehabilitation that leads to better outcomes.

Citing Articles

Comparison of Early Functional Recovery Following Triportal Robot-Assisted and Uniportal Video-Assisted Segmentectomy in Patients With Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis.

Wang Y, Diao H, Xu L, Peng Z Thorac Cancer. 2025; 16(5):e70041.

PMID: 40074689 PMC: 11903195. DOI: 10.1111/1759-7714.70041.


Assessing the performance of QLQ-C30 in predicting all-cause mortality in community cancer patients.

Zhao J, Wang Y, Huang W, Xu R, Yang X, Wang P BMC Cancer. 2025; 25(1):421.

PMID: 40055624 PMC: 11889892. DOI: 10.1186/s12885-025-13624-z.


Assessing the Relationship of Different Levels of Pain to the Health Status of Long-Term Breast Cancer Survivors: A Cross-Sectional Study.

Alvarez-Salvago F, Figueroa-Mayordomo M, Molina-Garcia C, Pujol-Fuentes C, Atienzar-Aroca S, de Diego-Moreno M Life (Basel). 2025; 15(2).

PMID: 40003586 PMC: 11856788. DOI: 10.3390/life15020177.


Remote symptom monitoring with patient-reported outcomes and nudges during lung cancer immunotherapy in China (PRO-NET): protocol for a randomised controlled trial.

Xia Y, Guan X, Shi Z, Luo Y, He P BMJ Open. 2025; 15(1):e093374.

PMID: 39880457 PMC: 11781134. DOI: 10.1136/bmjopen-2024-093374.


Describing quality of life trajectories in young Hispanic women with breast cancer: 5-year results from a large prospective cohort.

Vaca-Cartagena B, Ferrigno Guajardo A, Azim Jr H, Rotolo F, Olivas-Martinez A, Platas A Breast. 2025; 79:103866.

PMID: 39753060 PMC: 11755074. DOI: 10.1016/j.breast.2024.103866.


References
1.
Basch E, Spertus J, Dudley R, Wu A, Chuahan C, Cohen P . Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs). Value Health. 2015; 18(4):493-504. DOI: 10.1016/j.jval.2015.02.018. View

2.
Cocks K, King M, Velikova G, Martyn St-James M, Fayers P, Brown J . Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2010; 29(1):89-96. DOI: 10.1200/JCO.2010.28.0107. View

3.
Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

4.
Velikova G, Booth L, Smith A, Brown P, Lynch P, Brown J . Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004; 22(4):714-24. DOI: 10.1200/JCO.2004.06.078. View

5.
de Rooij B, Ezendam N, Mols F, Vissers P, Thong M, Vlooswijk C . Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: the population-based PROFILES registry. Qual Life Res. 2018; 27(12):3313-3324. PMC: 6244797. DOI: 10.1007/s11136-018-1979-0. View